References of "Van de Werf, Frans"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAcute coronary syndromes: considerations for improved acceptance and implementation of management guidelines.
Van de Werf, Frans; Ardissino, Diego; Bueno, Hector et al

in Expert Review of Cardiovascular Therapy (2012), 10(4), 489-503

The management of acute coronary syndrome in Europe is covered by various European Society of Cardiology guidelines, which although valuable, are complex and may not always provide clear guidance in ... [more ▼]

The management of acute coronary syndrome in Europe is covered by various European Society of Cardiology guidelines, which although valuable, are complex and may not always provide clear guidance in everyday clinical practice. Consequently, implementation of the guideline recommendations is frequently suboptimal. To complicate matters further, a wealth of new data from large trials examining novel anti-thrombotic agents will become or are already available, necessitating guideline updates. This article summarizes the gaps between current guideline-recommended treatment of acute coronary syndrome and daily practice as dictated by the evidence base, including recent trials. Reasons for the suboptimal implementation of the current European Society of Cardiology guidelines and possible solutions to making these more practice oriented are presented. [less ▲]

Detailed reference viewed: 12 (3 ULg)
Full Text
Peer Reviewed
See detailEarly versus delayed, provisional eptifibatide in acute coronary syndromes.
Giugliano, Robert P.; White, Jennifer A.; Bode, Christoph et al

in New England Journal of Medicine [=NEJM] (2009), 360(21), 2176-90

BACKGROUND: Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is ... [more ▼]

BACKGROUND: Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown. METHODS: We compared a strategy of early, routine administration of eptifibatide with delayed, provisional administration in 9492 patients who had acute coronary syndromes without ST-segment elevation and who were assigned to an invasive strategy. Patients were randomly assigned to receive either early eptifibatide (two boluses, each containing 180 microg per kilogram of body weight, administered 10 minutes apart, and a standard infusion > or = 12 hours before angiography) or a matching placebo infusion with provisional use of eptifibatide after angiography (delayed eptifibatide). The primary efficacy end point was a composite of death, myocardial infarction, recurrent ischemia requiring urgent revascularization, or the occurrence of a thrombotic complication during percutaneous coronary intervention that required bolus therapy opposite to the initial study-group [less ▲]

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailA statement on ethics from the HEART Group.
Ector, Hugo; LANCELLOTTI, Patrizio ULg; Roberts, William C. et al

in JACC. Cardiovascular Imaging (2008), 1(3), 410-2

Detailed reference viewed: 20 (1 ULg)